Key Takeaways
- • The Trump administration is reportedly preparing to limit future U.S. investments in Chinese biotechnology companies, according to The Wall Street Journal, while still permitting licensing arrangements.
- • The AMR Action Fund invested in TenNor Therapeutics, a Chinese biotech that recently completed an IPO, two years before the current report.
- • Despite the deal's quick payoff, AMR is unlikely to pursue new deals in China in the near term, according to the WSJ.
Summary
The Trump administration may restrict future U.S. investments in Chinese drugmakers, according to a Wall Street Journal report, while leaving licensing arrangements with Chinese biotechnology firms intact. The report frames the policy as a targeted limit on equity-style investment rather than a complete cutoff of cross-border drug development partnerships.
The article uses the AMR Action Fund as a case study. Two years ago, AMR invested in TenNor Therapeutics, a Chinese biotech that recently staged an initial public offering. Despite the quick payoff from that investment, the WSJ reports that AMR probably will not strike any new deals in China anytime soon, reflecting the chilling effect the potential restrictions could have on U.S. investors seeking exposure to Chinese biotech assets.
The source material available for this story is limited to the opening of the newsletter-style piece, so specific details on the scope of the proposed Treasury restrictions, timing, and affected transaction thresholds are not available here.
The article uses the AMR Action Fund as a case study. Two years ago, AMR invested in TenNor Therapeutics, a Chinese biotech that recently staged an initial public offering. Despite the quick payoff from that investment, the WSJ reports that AMR probably will not strike any new deals in China anytime soon, reflecting the chilling effect the potential restrictions could have on U.S. investors seeking exposure to Chinese biotech assets.
The source material available for this story is limited to the opening of the newsletter-style piece, so specific details on the scope of the proposed Treasury restrictions, timing, and affected transaction thresholds are not available here.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.